» Articles » PMID: 21831646

Mass Dose Effects and in Vivo Affinity in Brain PET Receptor Studies--a Study of Cerebral 5-HT4 Receptor Binding with [11C]SB207145

Overview
Journal Nucl Med Biol
Publisher Elsevier
Date 2011 Aug 12
PMID 21831646
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Attention to tracer dose principles is crucial in positron emission tomography (PET), and deviations can induce serious errors. In this study, we devise a method for determining receptor occupancy of the mass dose of the radioligand itself and the in vivo affinity.

Methods: The approach was used for [(11)C]SB207145, a new PET radioligand for imaging the cerebral 5-HT(4) receptors in humans. Test-retest PET studies with varying specific activities of [(11)C]SB207145 were conducted in seven healthy subjects, and the output parameter regional BP(ND) was modeled. Individual occupancy plots were first computed to estimate the mass dose that saturates 50% of receptors (ID(50)), and subsequently, the maximal mass dose that can be injected (arbitrarily set at an occupancy <5%) was calculated. Scatchard plots were computed to estimate the in vivo K(D).

Results: Increasing the mass dose resulted in a decrease in BP(ND), whilst the relative cerebellar uptake was unchanged. The ID(50) was 85.4±30.2 μg, and the upper mass dose limit was 4.5±1.6 μg, which does not require ultrahigh specific activity. The estimated in vivo K(D) was 2.8 nM (range 1.0-4.8), without any regional differences.

Conclusion: The presented method for estimating the upper mass dose limit is suggested as part of validation of PET radioligands.

Citing Articles

Numerical simulation method for the assessment of the effect of molar activity on the pharmacokinetics of radioligands in small animals.

Kikuchi T, Okamura T, Zhang M EJNMMI Radiopharm Chem. 2024; 9(1):78.

PMID: 39570519 PMC: 11582259. DOI: 10.1186/s41181-024-00308-5.


Stress Hormone Dynamics Are Coupled to Brain Serotonin 4 Receptor Availability in Unmedicated Patients With Major Depressive Disorder: A NeuroPharm Study.

Vulpius G, Kohler-Forsberg K, Ozenne B, Larsen S, Nasser A, Svarer C Int J Neuropsychopharmacol. 2023; 26(9):639-648.

PMID: 37542733 PMC: 10519814. DOI: 10.1093/ijnp/pyad041.


Sexual health and serotonin 4 receptor brain binding in unmedicated patients with depression-a NeuroPharm study.

Rasmussen A, Larsen S, Ozenne B, Kohler-Forsberg K, Stenbaek D, Jorgensen M Transl Psychiatry. 2023; 13(1):247.

PMID: 37414758 PMC: 10325956. DOI: 10.1038/s41398-023-02551-x.


Association between brain serotonin 4 receptor binding and reactivity to emotional faces in depressed and healthy individuals.

Sankar A, Ozenne B, Dam V, Svarer C, Jorgensen M, Miskowiak K Transl Psychiatry. 2023; 13(1):165.

PMID: 37169780 PMC: 10175268. DOI: 10.1038/s41398-023-02440-3.


Broad-scope Syntheses of [ C/ F]Trifluoromethylarenes from Aryl(mesityl)iodonium Salts.

Telu S, Jana S, Haskali M, Yang B, Jakobsson J, Zhao Q Chemistry. 2023; 29(24):e202204004.

PMID: 36652272 PMC: 10192059. DOI: 10.1002/chem.202204004.